Drugs / Oral Poliovirus Vaccine
last change Jun 2012 re-read 2 minutes ago

Oral Poliovirus Vaccine

Vaccine

Developed for
poliomyelitis
Investigated by
Merck Sharp & Dohme LLC

Trials 1 · a red edge is where a trial was stopped

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00130832 Oct 2005 → Jul 2006 Rotavirus infection, gastroenteritis Merck Sharp & Dohme LLC Completed No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01825109 Background Jul 2010 → Apr 2011 International Centre for Diarrhoeal Disease Research, Bangladesh Completed No outcome recorded
Phase 3 NCT01021293 Comparator Nov 2009 → Jul 2010 poliomyelitis GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT00829010 Background Feb 2009 → Jun 2011 streptococcal infection GlaxoSmithKline Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as oral poliovirus vaccine “co-administered with oral polio virus vaccine” NCT01825109
3

oral poliovirus vaccineNCT00829010

NCT01021293

NCT00130832

Known as Local OPV ClinicalTrials.gov intervention name — accepted as the source's own label NCT00829010
Known as OPV “received 3 doses of Oral Poliomyelitis Vaccine (OPV) at 2, 3 and 4 months of age, according to the vaccination policy recommended in China.” NCT01021293
1

“Comparator: Oral Poliovirus Vaccine (OPV)” NCT00130832

Known as Oral Poliomyelitis Vaccine (OPV) “received 3 doses of Oral Poliomyelitis Vaccine (OPV) at 2, 3 and 4 months of age, according to the vaccination policy recommended in China.” NCT01021293
Modality Vaccine “oral poliovirus vaccine (OPV)” NCT00130832
Route Oral “Comparator: Oral Poliovirus Vaccine (OPV)” NCT00130832